Virios Therapeutics (NASDAQ:VIRI – Get Free Report) had its price target increased by HC Wainwright from $0.20 to $5.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock.
Separately, Maxim Group started coverage on shares of Virios Therapeutics in a report on Thursday, June 20th. They issued a “buy” rating and a $1.00 target price on the stock.
View Our Latest Analysis on VIRI
Virios Therapeutics Stock Performance
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. On average, research analysts forecast that Virios Therapeutics will post -0.22 earnings per share for the current fiscal year.
About Virios Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
See Also
- Five stocks we like better than Virios Therapeutics
- ESG Stocks, What Investors Should Know
- 3 Momentum Trades for October With Ample Upside Ahead
- Health Care Stocks Explained: Why You Might Want to Invest
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- How to Use Stock Screeners to Find Stocks
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.